Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
A phase 3 trial of Talimogene laherparepvec and Pembrolizumab in Melanoma, run by Amgen, recorded as terminated on the registry.
Overview
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma is a phase 3 interventional study registered as NCT02263508 by Amgen, with 713 participants recorded, started 2014-12-08 and due to reach its primary completion in 2021-03-11. Interventions recorded: Talimogene Laherparepvec, Pembrolizumab, Placebo. Conditions recorded: Melanoma.
Linked to the drug Talimogene laherparepvec because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialAn Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
Shares Talimogene laherparepvec, Amgen, Melanoma and the tag pipeline.
- TrialEfficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
Shares Talimogene laherparepvec, Amgen, Melanoma and the tag pipeline.
- TrialStudy of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Shares Amgen and the tag pipeline.
- TrialA Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Shares Amgen and the tag pipeline.
- TrialX4P-001 and Pembrolizumab in Patients With Advanced Melanoma
Shares Melanoma, Pembrolizumab and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Melanoma, Pembrolizumab and the tag pipeline.
- TrialA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Shares Amgen and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.